Albany - NY, Oct. 20, 2015 (GLOBE NEWSWIRE) -- Rise in drug resistant species, launch of generics, and upcoming patent expirations during the period of 2015 to 2023 is likely to hamper the growth of the global antibacterial drugs market, states Transparency Market Research in its latest report. The 150-page research publication, titled "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023", indicates that registering a poor CAGR of 1.30% during the forecast period, the worldwide market for antibacterial drugs in projected to drop from US$43.9 Bn in 2014 to US$38.9 Bn by 2023.
Browse the full Antibacterial Drugs Market (By Class- Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides, Phenicols and Miscellaneous Antibacterials, and Pipeline Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 report at http://www.transparencymarketresearch.com/antibacterial-drugs-market.html
Antibacterial drugs are categorized into eight major classes: tetracyclines, β-Lactams, phenicols, macrolides, quinolones, aminoglycosides, sulfonamides, and miscellaneous antibacterials. Accounting for a 58% share in 2014, β-Lactams dominated the overall antibacterial drugs market. While quinolones held a 17% share that same year, this class of drugs is anticipated to register negative CAGR by the end of 2023. Growing geriatric population and rising demand for therapies against bacterial infections is likely to boost the miscellaneous antibacterials segment.
The strong pipeline in the antibacterial drugs market comprises Omadacycline (PTK-0796), SYM-1219, Zempia (E-101), Delamanid, Ozenoxacin, SPL7013, Eravacycline, Actoxumab / Aezlotoxumab (MK-3415A), Solithromycin (CEM-101), Ciprofloxacin/Fluocinolone Acetonide, Arikace, Carbavance (meropenem/RPX7009), RHB-105, Delafloxacin, Surotomycin (MK-4261), Cadazolid, and Plazomycin. Future commercialization of these antibacterial drugs is projected to boost the global market.
Geographically, the global antibacterial drugs market is divided into North America, Latin America, Europe, Asia Pacific, and Rest of the World. In terms of revenue, Asia Pacific dominates the antibacterial drugs market and is projected to also be the fastest developing regional segment by 2023. The growth in this region can be attributed to a number of factors including rising incidence of bacterial infections such as TB and MRSA, strong presence of generic and active pharmaceutical ingredient (API) manufacturers, growing purchasing power of the population, rise in geriatric population, developing healthcare infrastructure, and expanding population base.
Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1567
North America, followed by Europe, were the next largest markets for antibacterial drugs. The slow growth in these regions can be attributed to shortened product lifecycle, market maturity, generic infiltration, and strict regulatory requirements. AstraZeneca plc, Sanofi, Eli Lilly & Co., Merck & Co., Inc., GlaxoSmithKline plc, Bayer AG, Allergen plc, Bristol-Myers Squibb Company, Novartis AG, Pfizer, Inc., Johnson & Johnson, and Forest Laboratories, Inc. are the leading players functioning in the global antibacterial drugs market. Of these, Pfizer emerged as the leader as well as most promising player in the overall market.
The contribution and performance of each of these participants is analyzed on the basis of attributes such as company overview, financial standing, product portfolio, recent developments, and business strategies.
Global Antibacterial Drugs Market, by Drug Class, 2013 - 2023 (USD Million)
- Aminoglycosides
- B-Lactams
- Tetracyclines
- Sulfonamides
- Quinolones/Fluoroquinolones
- Macrolides
- Phenicols
- Miscellaneous Antibacterials
Pipeline Analysis of Antibacterial Drugs Market
- Actoxumab/Aezlotoxumab, (MK-3415A)
- Surotomycin (MK-4261)
- Arikace
- Cadazolid
- Ciprofloxacin/Fluocinolone Acetonide
- Zempia (E-101)
- Carbavance (meropenem/RPX7009)
- Ozenoxacin
- RHB-105
- SPL7013
- Delafloxacin
- Solithromycin (CEM-101)
- Eravacycline
- Delamanid
- SYM-1219
- Omadacycline (PTK-0796)
- Plazomycin
Global Antibacterial Drugs Market, by Geography, 2013 - 2023 (USD Million)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia-Pacific
- China
- Japan
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Rest of the World (RoW)
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.